Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE:JNJ) announced FDA approval (Jan 27, 2026) of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) combined with bortezomib, lenalidomide and dexamethasone (D-VRd) for adult newly diagnosed multiple myeloma patients who are transplant ineligible.
CEPHEUS Phase 3 results: overall MRD-negativity 52.3% vs 34.8% (sensitivity 10-5) at 22 months; sustained MRD≥12 months 42.6% vs 25.3% at 39 months; progression or death reduced 40% (HR 0.60; 95% CI 0.41–0.88). At ~59 months, complete response or better was 81.2% vs 61.6%. Overall survival data not yet mature.
Johnson & Johnson (NYSE: JNJ) announced it has donated $100 million of MedTech products since 2020 and plans an additional $20 million in 2026 to support programs and impact investments that expand access to cardiovascular, surgical and vision care. These commitments operate under J&J CareCommunity and involve partners including Lions Clubs International Foundation, Operation Smile, American Heart Association and Global Surgery Foundation. The effort reaches over 300,000 healthcare professionals annually and includes a $1 million commitment to SURGfund and long‑running programs such as Sight For Kids, which has reached > 55 million students.
Johnson & Johnson (NYSE: JNJ) reported Q4 2025 sales of $24.6B (+9.1% reported; operational +7.1%) and full‑year 2025 sales of $94.2B (+6.0% reported; operational +5.3%).
Q4 diluted EPS was $2.10 and full‑year diluted EPS was $11.03; adjusted diluted EPS was $2.46 for Q4 and $10.79 for full year. Results include a $(0.10) EPS impact from the acquisition of Halda Therapeutics. Free cash flow for 2025 is ~$19.7B.
Notable developments: FDA approvals (including CAPLYTA and RYBREVANT FASPRO plus LAZCLUZE), landmark TECVAYLI plus DARZALEX FASPRO data, completion of the Halda acquisition, and submission of the OTTAVA robotic surgical system. 2026 guidance midpoint: estimated reported sales $100.5B (+6.7%) and adjusted EPS $11.53 (+6.9%).
Johnson & Johnson (NYSE:JNJ) reported positive topline Phase 3 MajesTEC-9 results for TECVAYLI monotherapy in relapsed/refractory multiple myeloma. TECVAYLI reduced the risk of disease progression or death by 71% (HR=0.29, 95% CI: 0.23–0.38) and the risk of death by 40% (HR=0.60, 95% CI: 0.43–0.83) versus standard of care. The trial enrolled patients with 1–3 prior therapies; most were refractory to anti‑CD38 (85%) and lenalidomide (79%). Safety was described as clinically manageable with no new safety concerns; the IDMC recommended unblinding after a pre‑specified interim analysis. Full results will be presented at a future medical meeting.
Johnson & Johnson (NYSE: JNJ) will present 11 abstracts at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Jan 12–15, 2026, in Nassau, Bahamas. Presentations cover Phase 3 and preclinical neuropsychiatry research across major depressive disorder (MDD), treatment-resistant depression (TRD), schizophrenia, and discovery work.
Key items include Phase 3 analyses of lumateperone (CAPLYTA) for remission in adjunctive MDD, metabolic and tolerability data comparing adjunctive seltorexant vs quetiapine XR in MDD with insomnia, and post-hoc Phase 3 analyses of esketamine (SPRAVATO) on anhedonia in TRD, plus AI and biomarker discovery posters.
Johnson & Johnson (NYSE:JNJ) reported longer-term Phase 1b/2 OrigAMI-1 results for amivantamab (RYBREVANT) combined with FOLFOX or FOLFIRI in RAS/BRAF wild-type metastatic colorectal cancer at ASCO GI 2026. At a median 16-month follow-up, confirmed ORR was 51% overall and 73% in the first-line subgroup; median DOR was 9.3 months overall and not reached in first-line. Median PFS was 9.2 months overall and 11.3 months in patients with liver metastases. Safety was consistent with known profiles; 9% discontinued for treatment-related adverse events and neutropenia was the most common Grade ≥3 event.
Johnson & Johnson (NYSE: JNJ) announced a voluntary agreement with the U.S. government to improve access to medicines, including participation in TrumpRx.gov to offer discounted prices to millions of American patients and an exemption for JNJ pharmaceutical products from U.S. tariffs. The company reaffirmed its $55 billion U.S. investment commitment through early 2029 and announced two new U.S. manufacturing facilities: a next‑generation cell therapy site in Pennsylvania and a drug product facility in North Carolina. Construction continues on a $2 billion biologics facility in Wilson, NC, expected to create ~5,000 skilled jobs; JNJ also secured a 160,000+ sq ft site in Holly Springs, NC.
Summary not available.
Johnson & Johnson (NYSE: JNJ) submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration on January 7, 2026, requesting De Novo classification for multiple general surgery procedures in the upper abdomen.
The submission uses data from a completed Investigational Device Exemption (IDE) clinical study (first cases completed in early 2025) and targets procedures such as gastric bypass, gastric sleeve, small bowel resection and hiatal hernia repair. A second IDE was approved in late 2025 to begin a U.S. trial in inguinal hernia repair. The OTTAVA system remains under development and is not authorized for marketing or sale.
Johnson & Johnson (NYSE: JNJ) announced positive topline Phase 2b JASMINE results for nipocalimab in systemic lupus erythematosus (SLE) on January 6, 2026. The study met its primary endpoint (percentage achieving SRI-4 at Week 24 versus placebo) and key secondary/exploratory endpoints, including signals for steroid sparing. JASMINE enrolled 228 adults in a 52-week, randomized, double-blind, placebo-controlled, dose-ranging trial. Nipocalimab's safety and tolerability were consistent with prior Phase 2 studies with no new safety signals identified. Based on these topline results, the company plans to initiate a Phase 3 program for SLE; full study data will be presented at a future medical congress.